Losartan and diabetic nephropathy: commentaries on the RENAAL study

  title={Losartan and diabetic nephropathy: commentaries on the RENAAL study},
  author={Enrique Z Fisman and Alexander Tenenbaum and Michael Motro},
  journal={Cardiovascular Diabetology},
  pages={2 - 2}
The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study is a multinational, double-blind, randomized, placebo controlled trial which was recently published. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in patients with diabetic nephropathy. The primary efficacy measure was the time to the first event of the composite end point of a doubling of serum creatinine, end-stage renal disease, or death. The conclusion was that… CONTINUE READING
3 Extracted Citations
16 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…